Home
Technology
The Problem
Recognition
Vision
Contact
Contact Us
Gene Panel
0
Cancer Types Validated
0
Samples Validated
0

World leaders in Tumor Educated Platelets-based early cancer diagnostics

TEPScan™ is our patented liquid biopsy — a single blood draw, an 11-gene platelet panel and proprietary AI — built to catch cancer early, accurately and at very low cost.
Learn More

A new generation of liquid biopsies, validated across 11+ cancer types at a fraction of today's cost.

See the Data
Cancer Types Validated
11 Types
Head & Neck liquid biopsy validation sample
Head & Neck
Module Overview
Validated on 107 clinical samples using our 11-gene TEP panel, with results delivered in ~2.5 hours from a single 6ml blood draw.
View Validation Data
NSCLC liquid biopsy validation sample
NSCLC
Module Overview
Validated on 10 clinical samples using our 11-gene TEP panel, with results delivered in ~2.5 hours from a single 6ml blood draw.
View Validation Data
Breast liquid biopsy validation sample
Breast
Module Overview
Validated on 47 clinical samples using our 11-gene TEP panel, with results delivered in ~2.5 hours from a single 6ml blood draw.
View Validation Data
Ovary liquid biopsy validation sample
Ovary
Module Overview
Validated on 28 clinical samples using our 11-gene TEP panel, with results delivered in ~2.5 hours from a single 6ml blood draw.
View Validation Data
Prostate liquid biopsy validation sample
Prostate
Module Overview
Validated on 17 clinical samples using our 11-gene TEP panel, with results delivered in ~2.5 hours from a single 6ml blood draw.
View Validation Data
Kidney liquid biopsy validation sample
Kidney
Module Overview
Validated on 6 clinical samples using our 11-gene TEP panel, with results delivered in ~2.5 hours from a single 6ml blood draw.
View Validation Data
Colon liquid biopsy validation sample
Colon
Module Overview
Validated on 4 clinical samples using our 11-gene TEP panel, with results delivered in ~2.5 hours from a single 6ml blood draw.
View Validation Data
Pancreas liquid biopsy validation sample
Pancreas
Module Overview
Validated on 4 clinical samples using our 11-gene TEP panel, with results delivered in ~2.5 hours from a single 6ml blood draw.
View Validation Data
Thyroid liquid biopsy validation sample
Thyroid
Module Overview
Validated on 4 clinical samples using our 11-gene TEP panel, with results delivered in ~2.5 hours from a single 6ml blood draw.
View Validation Data
Soft Tissue liquid biopsy validation sample
Soft Tissue
Module Overview
Validated on 2 clinical samples using our 11-gene TEP panel, with results delivered in ~2.5 hours from a single 6ml blood draw.
View Validation Data
Gastric liquid biopsy validation sample
Gastric
Module Overview
Validated on 1 clinical sample using our 11-gene TEP panel, with results delivered in ~2.5 hours from a single 6ml blood draw.
View Validation Data

What makes TEPScan™ different

Detect Affordably
Catch cancer at Stage I, before symptoms appear
TEPScan™'s 11-gene platelet panel is built to flag early-stage disease — 47% of samples validated to date were Stage I or II, when treatment options are strongest.
See the Data
A liquid biopsy priced for population-scale screening
At a target price of ~$150 per test, versus $450–$1,000+ for competing platforms like Galleri, Guardant and Thrive, TEPScan™ is built to make early screening accessible at scale.
See the Data
Runs on the RT-PCR machines labs already own
No specialised sequencing infrastructure required — any molecular diagnostics lab that can run a standard RT-PCR test can run TEPScan™, from a single 6ml blood draw.
See the Data
Backed by peer-reviewed research and multi-country validation
Validated across 297 samples spanning 11+ cancer types, with an average accuracy (AUC) of ~91%, and research cited by scientists in Germany, China and beyond.
See the Data
Smiling female dentist in a white coat showing a dental model to a seated patient.
Man standing and presenting with a clipboard to four seated colleagues in a bright office with large windows.
Close-up of a robotic arm with tubing and mechanical parts inside a lab or manufacturing environment with blue lighting.
Low-angle view of a classical building facade featuring six tall Corinthian columns and detailed sculptural frieze under a clear blue sky, flanked by modern buildings.
Smiling female dentist in a white coat showing a dental model to a seated patient.
1
If cancer is only found after symptoms appear, it's already too late.
That's the reality for 75% of patients today.
Late detection drives nearly 10 million deaths a year, across every continent.
Undiagnosed
Untreated
Unaffordable
Inaccessible
Invasive
Too Late
What if a single blood draw could change that?
Abstract red and pink swirling particles forming soft, flowing shapes.
Built to catch cancer while it can still be beaten.
Early Detection
Low Cost
Global Access
At Care Onco Biotech, we're building India's first cancer-specific medical unicorn — using Tumor Educated Platelets to bring low-cost, early cancer detection to the world, and giving clinicians a better tool for Minimum Residual Disease (MRD) analysis and early indication of remission.
Get in Touch
Backed by science

TEPScan™ research is already being cited by scientists around the world

Rybczynska et al., 2021
University of Groningen
“More recently, expression levels of an 11-gene panel that included ITGA2B in platelets was shown to identify NSCLC patients with high accuracy.”
Meng et al., 2021
China Medical University
“Chitrita Goswami et al. proposed 11 platelet genes providing a reliable and economically viable classification between NSCLC and healthy samples.”
Zhang et al., 2021
Independent research
“The vast majority of NSCLC patients are diagnosed at an advanced stage because early diagnosis is not possible without clear symptoms.”

Answers that help you
evaluate TEPScan™

Need help?
Get in touch with us
Contact Us
What is TEPScan™?
Plus icon, svg, dark

TEPScan™ is our patented liquid biopsy platform, built on Tumor Educated Platelets (TEPs). From a single 6ml blood draw, we extract RNA from platelets, run qRT-PCR on an 11-gene panel and use a proprietary AI model to predict the presence of cancer in around 2.5 hours.

The gene panel was discovered and patented by our scientific founders at IIIT-Delhi and has already been cited in independent peer-reviewed research from institutions including the University of Groningen and China Medical University.

How is TEPScan™ different from Galleri, Guardant or Thrive?
Plus icon, svg, dark

Existing liquid biopsies such as Grail's Galleri, Guardant's Lunar 2 and Thrive's CancerSEEK rely on circulating tumour DNA and cost $450–$1,000+ per test, with 7–14 day turnaround times, and are largely inaccessible outside specialised labs.

TEPScan™ is designed to run on standard RT-PCR machines that most molecular diagnostics labs already own, at a target price of ~$150 per test, with results in ~2.5 hours — making early detection more accessible and affordable at scale.

How accurate is TEPScan™?
Plus icon, svg, dark

Across 297 validated clinical samples spanning 11+ cancer types, TEPScan™ has shown an average accuracy (AUC) of approximately 91%, with 47% of validated samples representing early-stage (Stage I and II) cancers.

Validation has progressed across multiple sites, including a government-funded study with the University Hospital of Stavanger in Norway focused on breast cancer.

What is the current regulatory and commercial status?
Plus icon, svg, dark

We are currently completing kit formulation and have begun CDSCO and regulatory engagement in 2026. Our path to market includes an India RUO (Research Use Only) launch of the TEPScan™ test for NSCLC and Head & Neck cancers, followed by a commercial test kit covering three cancer types with contract manufacturing and global marketing partnerships.

We are raising ₹50 crore to fund clinical validation, regulatory approval, R&D, lab infrastructure and commercialisation over the next three years.

Can any lab run the TEPScan™ test?
Plus icon, svg, dark

Yes. TEPScan™ is built to be scalable: any molecular diagnostics lab in the world equipped to run a standard RT-PCR test — the same infrastructure most labs already use for COVID-19 testing — can run TEPScan™.

Labs upload their test data to our AI-powered cloud application, and a report is processed and emailed back the same day, for a fee included in the kit cost.

Need help?
Get in touch with us
Contact Us
Ready to bring low-cost, early cancer detection to your market? Let's talk.
Schedule an investor call